1283 related articles for article (PubMed ID: 17388006)
21. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Mar; 57(3):380-6. PubMed ID: 18249211
[TBL] [Abstract][Full Text] [Related]
22. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
[TBL] [Abstract][Full Text] [Related]
23. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
24. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Milionis HJ; Kakafika AI; Tsouli SG; Athyros VG; Bairaktari ET; Seferiadis KI; Elisaf MS
Am Heart J; 2004 Oct; 148(4):635-40. PubMed ID: 15459594
[TBL] [Abstract][Full Text] [Related]
25. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
26. Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Mehta A; Shah U; Parikh K; Chag M; Baxi H; Chandarana A; Naik A; Naik A; Shah K; Goyal R
Can J Physiol Pharmacol; 2007 Jun; 85(6):628-33. PubMed ID: 17823625
[TBL] [Abstract][Full Text] [Related]
27. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
28. Addressing the challenge.
Olsson AG
Eur Heart J; 1998 Oct; 19 Suppl M():M29-35. PubMed ID: 9821014
[TBL] [Abstract][Full Text] [Related]
29. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
[TBL] [Abstract][Full Text] [Related]
30. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
31. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
Zeman M; Zák A; Vecka M; Romaniv S
Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
[TBL] [Abstract][Full Text] [Related]
32. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Davidson MH
Am J Cardiol; 2005 Nov; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008
[TBL] [Abstract][Full Text] [Related]
33. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
Ansell BJ; Watson KE; Weiss RE; Fonarow GC
Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
Chatley P; Badyal DK; Calton R; Khosla PP
Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):217-21. PubMed ID: 17520105
[TBL] [Abstract][Full Text] [Related]
35. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
37. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
Udawat H; Goyal RK
Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
39. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
